Skip to main content

What the FDA labels say about taking them together

Dabrafenib and midazolam

Dabrafenib's FDA label of May 20, 2026 names midazolam in its drug interactions section; the midazolam labels PlainMeds reads (4) do not name dabrafenib. The dabrafenib label: “Dabrafenib decreased the systemic exposures of midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), and R-warfarin.”

Check it at the source: the dabrafenib FDA label on DailyMed (effective May 20, 2026, Novartis Pharmaceuticals Corporation); the midazolam FDA label on DailyMed (effective January 1, 2024, Fresenius Kabi USA, LLC).

What does the dabrafenib label say about midazolam?

Dabrafenib label, drug interactions

Dabrafenib decreased the systemic exposures of midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), and R-warfarin (a CYP3A4/CYP1A2 substrate) [see Clinical Pharmacology (12.3)].

Source: FDA drug label (Tafinlar), Novartis Pharmaceuticals Corporation, effective May 20, 2026 (SPL set fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea), via openFDA; the full label on DailyMed

What does the midazolam label say about dabrafenib?

Midazolam's label (effective January 1, 2024) and its 3 other brand-application labels do not name dabrafenib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Midazolam), Fresenius Kabi USA, LLC, effective January 1, 2024 (SPL set 1cc9ba6e-fa1b-405e-9de8-720c567b2a73), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Dabrafenib generic labelers
22Midazolam generic labelers
DabrafenibMidazolam
Labeled forLung cancern/a
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$0.233 per mL 2 mg/2 mL vial
Shortage nowNo current entryIn shortage

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?